Next Article in Journal / Special Issue
A New Cold Plasma Jet: Performance Evaluation of Cold Plasma, Hybrid Plasma and Argon Plasma Coagulation
Previous Article in Journal
Structure and Stability of C:H:O Plasma Polymer Films Co-Polymerized Using Dimethyl Carbonate
Previous Article in Special Issue
New Hopes for Plasma-Based Cancer Treatment
Article Menu

Export Article

Open AccessArticle
plasma 2018, 1(1), 177-188; https://doi.org/10.3390/plasma1010016

The Canady Helios Cold Plasma Scalpel Significantly Decreases Viability in Malignant Solid Tumor Cells in a Dose-Dependent Manner

1
Jerome Canady Research Institute for Advanced Biological and Technological Sciences, Takoma Park, MD 20912, USA
2
Plasma Medicine Life Sciences, Takoma Park, MD 20912, USA
3
Department of Surgery, University of Massachusetts School of Medicine, Worcester, MA 01655, USA
4
School of Engineering & Applied Science, The George Washington University, Washington, DC 20052, USA
The authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 19 July 2018 / Revised: 10 August 2018 / Accepted: 24 August 2018 / Published: 7 September 2018
(This article belongs to the Special Issue Plasma Medicine)
Full-Text   |   PDF [3310 KB, uploaded 10 September 2018]   |  

Abstract

To determine appropriate treatment doses of cold atmospheric plasma (CAP), the Canady Helios Cold Plasma Scalpel was tested across numerous cancer cell types including renal adenocarcinoma, colorectal carcinoma, pancreatic adenocarcinoma, ovarian adenocarcinoma, and esophageal adenocarcinoma. Various CAP doses were tested consisting of both high (3 L/min) and low (1 L/min) helium flow rates, several power settings, and a range of treatment times up to 5 min. The impact of cold plasma on the reduction of viability was consistently dose-dependent; however, the anti-cancer capability varied significantly between cell lines. While the lowest effective dose varied from cell line to cell line, in each case an 80–99% reduction in viability was achievable 48 h after CAP treatment. Therefore, it is critical to select the appropriate CAP dose necessary for treating a specific cancer cell type. View Full-Text
Keywords: cold atmospheric plasma; CAP; cancer therapy; dose-dependent; renal adenocarcinoma; colorectal carcinoma; pancreatic adenocarcinoma; ovarian adenocarcinoma; esophageal adenocarcinoma cold atmospheric plasma; CAP; cancer therapy; dose-dependent; renal adenocarcinoma; colorectal carcinoma; pancreatic adenocarcinoma; ovarian adenocarcinoma; esophageal adenocarcinoma
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Rowe, W.; Cheng, X.; Ly, L.; Zhuang, T.; Basadonna, G.; Trink, B.; Keidar, M.; Canady, J. The Canady Helios Cold Plasma Scalpel Significantly Decreases Viability in Malignant Solid Tumor Cells in a Dose-Dependent Manner. plasma 2018, 1, 177-188.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
plasma EISSN 2571-6182 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top